Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial.

DeZure AD, Coates EE, Hu Z, Yamshchikov GV, Zephir KL, Enama ME, Plummer SH, Gordon IJ, Kaltovich F, Andrews S, McDermott A, Crank MC, Koup RA, Schwartz RM, Bailer RT, Sun X, Mascola JR, Tumpey TM, Graham BS, Ledgerwood JE.

NPJ Vaccines. 2017 Jun 1;2:15. doi: 10.1038/s41541-017-0016-6. eCollection 2017.

2.

DNA priming for seasonal influenza vaccine: a phase 1b double-blind randomized clinical trial.

Ledgerwood JE, Bellamy AR, Belshe R, Bernstein DI, Edupuganti S, Patel SM, Renehan P, Zajdowicz T, Schwartz R, Koup R, Bailer RT, Yamshchikov GV, Enama ME, Sarwar U, Larkin B, Graham BS; VRC 701 study team.

PLoS One. 2015 May 7;10(5):e0125914. doi: 10.1371/journal.pone.0125914. eCollection 2015.

3.

Phase 1 study of pandemic H1 DNA vaccine in healthy adults.

Crank MC, Gordon IJ, Yamshchikov GV, Sitar S, Hu Z, Enama ME, Holman LA, Bailer RT, Pearce MB, Koup RA, Mascola JR, Nabel GJ, Tumpey TM, Schwartz RM, Graham BS, Ledgerwood JE; VRC 308 Study Team.

PLoS One. 2015 Apr 17;10(4):e0123969. doi: 10.1371/journal.pone.0123969. eCollection 2015.

4.

Publication practices and attitudes towards evidence-based medicine in central Asia.

Yamshchikov GV, Schmid GP.

Lancet Glob Health. 2013 Aug;1(2):e73-e74. doi: 10.1016/S2214-109X(13)70022-6. Epub 2013 Jul 24. No abstract available.

5.

Evaluation of the sentinel immunized node for immune monitoring of cancer vaccines.

Slingluff CL Jr, Yamshchikov GV, Hogan KT, Hibbitts SC, Petroni GR, Bissonette EA, Patterson JW, Neese PY, Grosh WW, Chianese-Bullock KA, Czarkowski A, Rehm PK, Parekh J.

Ann Surg Oncol. 2008 Dec;15(12):3538-49. doi: 10.1245/s10434-008-0046-4. Epub 2008 Oct 16.

6.

Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting.

Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, Smolkin ME, Hibbitts S, Murphy C, Johansen N, Grosh WW, Yamshchikov GV, Neese PY, Patterson JW, Fink R, Rehm PK.

Clin Cancer Res. 2007 Nov 1;13(21):6386-95.

7.

Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells.

Chang CC, Ogino T, Mullins DW, Oliver JL, Yamshchikov GV, Bandoh N, Slingluff CL Jr, Ferrone S.

J Biol Chem. 2006 Jul 7;281(27):18763-73. Epub 2006 Apr 28.

8.

Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma.

Yamshchikov GV, Mullins DW, Chang CC, Ogino T, Thompson L, Presley J, Galavotti H, Aquila W, Deacon D, Ross W, Patterson JW, Engelhard VH, Ferrone S, Slingluff CL Jr.

J Immunol. 2005 Jun 1;174(11):6863-71.

9.

Low-dose IL-2 induces cytokine cascade, eosinophilia, and a transient Th2 shift in melanoma patients.

Cragun WC, Yamshchikov GV, Bissonette EA, Smolkin ME, Eastham S, Petroni GR, Schrecengost RS, Woodson EM, Slingluff CL Jr.

Cancer Immunol Immunother. 2005 Nov;54(11):1095-105. Epub 2005 May 12.

PMID:
15889250
10.

Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule.

Slingluff CL Jr, Petroni GR, Yamshchikov GV, Hibbitts S, Grosh WW, Chianese-Bullock KA, Bissonette EA, Barnd DL, Deacon DH, Patterson JW, Parekh J, Neese PY, Woodson EM, Wiernasz CJ, Merrill P.

J Clin Oncol. 2004 Nov 15;22(22):4474-85.

PMID:
15542798
11.

Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.

Slingluff CL Jr, Petroni GR, Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, Hibbitts S, Teates D, Neese PY, Grosh WW, Chianese-Bullock KA, Woodson EM, Wiernasz CJ, Merrill P, Gibson J, Ross M, Engelhard VH.

J Clin Oncol. 2003 Nov 1;21(21):4016-26.

PMID:
14581425
12.

Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients.

Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, Teates D, Neese P, Grosh WW, Petroni G, Engelhard VH, Slingluff CL Jr.

Int J Cancer. 2001 Jun 1;92(5):703-11.

13.

Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines.

Brinckerhoff LH, Kalashnikov VV, Thompson LW, Yamshchikov GV, Pierce RA, Galavotti HS, Engelhard VH, Slingluff CL Jr.

Int J Cancer. 1999 Oct 29;83(3):326-34.

14.

Assembly of SIV virus-like particles containing envelope proteins using a baculovirus expression system.

Yamshchikov GV, Ritter GD, Vey M, Compans RW.

Virology. 1995 Dec 1;214(1):50-8.

15.

Protection against vaginal SIV transmission with microencapsulated vaccine.

Marx PA, Compans RW, Gettie A, Staas JK, Gilley RM, Mulligan MJ, Yamshchikov GV, Chen D, Eldridge JH.

Science. 1993 May 28;260(5112):1323-7.

PMID:
8493576
16.

Cytoplasmic domain truncation enhances fusion activity by the exterior glycoprotein complex of human immunodeficiency virus type 2 in selected cell types.

Mulligan MJ, Yamshchikov GV, Ritter GD Jr, Gao F, Jin MJ, Nail CD, Spies CP, Hahn BH, Compans RW.

J Virol. 1992 Jun;66(6):3971-5.

17.

Human immunodeficiency virus type 2 envelope glycoprotein: differential CD4 interactions of soluble gp120 versus the assembled envelope complex.

Mulligan MJ, Ritter GD Jr, Chaikin MA, Yamshchikov GV, Kumar P, Hahn BH, Sweet RW, Compans RW.

Virology. 1992 Mar;187(1):233-41.

PMID:
1736526

Supplemental Content

Loading ...
Support Center